Autoimmune hemolytic anemia (AIHA) is a highly heterogeneous disease due to increased destruction of autologous erythrocytes by autoantibodies with or without complement involvement. Other pathogenic mechanisms include hyper-activation of cellular immune effectors, cytokine dysregulation, and ineffective marrow compensation.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Measure prevalence of AIHA in MM patients .
Timeframe: baseline
Detect impact on International Prognostic Scoring System
Timeframe: baseline
Detect impact on outcome
Timeframe: through study completion, an average of 1 year